Double-stranded RNA-mediated interference (RNAi), antisense oligonucleotides (ASO), and ribozymes have excellent specificity to their target oncogenic mRNA. They also seem to show great promise when it comes to treating cancer. The problem is that RNAi, ASO, and ribozymes ha ve poor stability and are constantly being degraded by nucleases. Researchers have made some efforts to increase antisense oligonucleotides’ stability by creating phospharimidate and Phosphorothioate. Currently, ribozymes, antisense oligonucleotides, and (RNAi) are the three main methods used to target RNA. These methods are currently undergoing clinical trials for the purpose of focusing on specific RNAs involved in disorders like cancer and neurodegeneration. In fact, ASOs that target amyotrophic lateral sclerosis and spinal muscular atrophy have produced promising results in clinical trials. The formation of chemical alterations that boost affinity and selectivity while reducing noxiousness owing to off-target impacts are two benefits of ASOs. Another benefit is increased affinity. With a focus on RNAi and ASOs, this review illustrated the main therapeutic strategies of RNA therapy now in use.
Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
Wang, D., et al. (2016) Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano letters, 16, 5503-5513. https://doi.org/10.1021/acs.nanolett.6b01994
Bray, F., Laversanne, M., Weiderpass, E. and Soerjomataram, I. (2021) The Ever-Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide. Cancer, 127, 3029-3030. https://doi.org/10.1002/cncr.33587
Topper, M.J., Vaz, M., Marrone, K.A., Brahmer, J.R. and Baylin, S.B. (2020) The Emerging Role of Epigenetic Therapeutics in Immuno-Oncology. Nature Reviews Clinical Oncology, 17, 75-90. https://doi.org/10.1038/s41571-019-0266-5
Cox, V.L., et al. (2017) Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology, 283, 314-340. https://doi.org/10.1148/radiol.2017152224
Hardin, J., Bertoni, G.P. and Kleinsmith, L.J. (2017) Becker’s World of the Cell, eBook. Pearson Higher Education, London.
Dunnett-Kane, V., et al. (2020) Germline and Sporadic Cancers Driven by the RAS Pathway: Parallels and Contrasts. Annals of Oncology, 31, 873-883. https://doi.org/10.1016/j.annonc.2020.03.291
Kelly, K., et al. (2015) Adjuvant Erlotinib versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 33, 4007-4014. https://doi.org/10.1200/JCO.2015.61.8918
Lee, S.M., et al. (2014) Randomized Trial of Erlotinib plus Whole-Brain Radiotherapy for NSCLC Patients with Multiple Brain Metastases. JNCI: Journal of the National Cancer Institute, 106, Article No. dju151. https://doi.org/10.1093/jnci/dju151
Novello, S. (2015) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33, 3985-3986. https://doi.org/10.1200/JCO.2015.63.7587
Khan, P., et al. (2021) RNA-Based Therapies: A Cog in the Wheel of Lung Cancer Defense. Molecular Cancer, 20, Article No. 54. https://doi.org/10.1186/s12943-021-01338-2
Rossor, A.M., Reilly, M.M. and Sleigh, J.N. (2018) Antisense Oligonucleotides and Other Genetic Therapies Made Simple. Practical Neurology, 18, 126-131. https://doi.org/10.1136/practneurol-2017-001764
Chery, L., et al. (2016) Demographic and Clinical Profiles of Plasmodium falciparum and Plasmodium vivax Patients at a Tertiary Care Centre in Southwestern India. Malaria Journal, 15, Article No. 569. https://doi.org/10.1186/s12936-016-1619-5
Lavrovsky, Y., Chen, S. and Roy, A.K. (2019) Triplex and Ribozyme Technology in Gene Repression. In: Thomas, J.A., Ed., Biotechnology and Safety Assessment, CRC Press, Boca Raton, 109-126. https://doi.org/10.1201/9780367811662-5
Blair, C.D. and Olson, K.E. (2015) The Role of RNA Interference (RNAi) in Arbovirus-Vector Interactions. Viruses, 7, 820-843. https://doi.org/10.3390/v7020820
Einstein, J.M., et al. (2021) Inhibition of YTHDF2 Triggers Proteotoxic Cell Death in MYC-Driven Breast Cancer. Molecular Cell, 81, 3048-3064. https://doi.org/10.1016/j.molcel.2021.06.014
Zhang, Y., Yang, M., Yang, S. and Hong, F. (2022) Role of Noncoding RNAs and Untranslated Regions in Cancer: A Review. Medicine, 101, e30045. https://doi.org/10.1097/MD.0000000000030045
Finkel, R.S., et al. (2016) Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study. The Lancet, 388, 3017-3026. https://doi.org/10.1016/S0140-6736(16)31408-8
Li, Z. and Rana, T.M. (2014) Therapeutic Targeting of microRNAs: Current Status and Future Challenges. Nature Reviews Drug Discovery, 13, 622-638. https://doi.org/10.1038/nrd4359
Huang, Y., Bai, J.Y. and Ren, H.T. (2014) PiRNA Biogenesis and Its Functions. Russian Journal of Bioorganic Chemistry, 40, 293-299. https://doi.org/10.1134/S1068162014030169
Schumann, G.G., et al. (2019) The Impact of Transposable Element Activity on therapeutically Relevant Human Stem Cells. Mobile DNA, 10, Article No. 9. https://doi.org/10.1186/s13100-019-0151-x
Drongitis, D., Aniello, F., Fucci, L. and Donizetti, A. (2019) Roles of Transposable Elements in the Different Layers of Gene Expression Regulation. International Journal of Molecular Sciences, 20, Article No. 5755. https://doi.org/10.3390/ijms20225755
Ozata, D.M., Gainetdinov, I., Zoch, A., O’Carroll, D. and Zamore, P.D. (2019) PIWI-Interacting RNAs: Small RNAs with Big Functions. Nature Reviews Genetics, 20, 89-108. https://doi.org/10.1038/s41576-018-0073-3
Rüger, J., Ioannou, S., Castanotto, D. and Stein, C.A. (2020) Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019. Trends in Pharmacological Sciences, 41, 27-41. https://doi.org/10.1016/j.tips.2019.10.009
Ebenezer, O., Comoglio, P., Wong, G.K.-S. and Tuszynski, J.A. (2023) Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences, 24, Article No. 4019. https://doi.org/10.3390/ijms24044019
French, L.S., Mellough, C.B., Chen, F.K. and Carvalho, L.S. (2020) A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome. Frontiers in Cellular Neuroscience, 14, Article 183. https://doi.org/10.3389/fncel.2020.00183
Dammes, N. and Peer, D. (2020) Paving the Road for RNA Therapeutics. Trends in Pharmacological Sciences, 41, 755-775. https://doi.org/10.1016/j.tips.2020.08.004
Hernández, A.R., Peterson, L.W. and Kool, E.T. (2012) Steric Restrictions of RISC in RNA Interference Identified with Size-Expanded RNA Nucleobases. ACS Chemical Biology, 7, 1454-1461. https://doi.org/10.1021/cb300174c
Xing, Y., et al. (2021) Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression. Frontiers in Immunology, 12, Article 624725. https://doi.org/10.3389/fimmu.2021.624725
Yi, M., et al. (2020) The Role of Cancer-Derived microRNAs in Cancer Immune Escape. Journal of Hematology & Oncology, 13, Article No. 25. https://doi.org/10.1186/s13045-020-00848-8
Hsin, J.-P., et al. (2018) The Effect of Cellular Context on miR-155-Mediated Gene Regulation in Four Major Immune Cell Types. Nature Immunology, 19, 1137-1145. https://doi.org/10.1038/s41590-018-0208-x
Wang, H., et al. (2019) Multiple Roles of microRNA-146a in Immune Responses and Hepatocellular Carcinoma. Oncology Letters, 18, 5033-5042. https://doi.org/10.3892/ol.2019.10862
Tavasolian, F., Hosseini, A.Z., Soudi, S. and Naderi, M. (2020) MiRNA-146a Improves Immunomodulatory Effects of MSC-DERIVED EXOsomes in Rheumatoid Arthritis. Current Gene Therapy, 20, 297-312. https://doi.org/10.2174/1566523220666200916120708
Mortazavi-Jahromi, S.S., Aslani, M. and Mirshafiey, A. (2020) A Comprehensive Review on miR-146a Molecular Mechanisms in a Wide Spectrum of Immune and Non-Immune Inflammatory Diseases. Immunology Letters, 227, 8-27. https://doi.org/10.1016/j.imlet.2020.07.008
Alizadeh, M., et al. (2019) The Potential Role of miR-29 in Health and Cancer Diagnosis, Prognosis, and Therapy. Journal of Cellular Physiology, 234, 19280-19297. https://doi.org/10.1002/jcp.28607
Anastasiadou, E., et al. (2019) Epstein-Barr Virus-Encoded EBNA2 Alters Immune Checkpoint PD-L1 Expression by Downregulating miR-34a in B-Cell Lymphomas. Leukemia, 33, 132-147. https://doi.org/10.1038/s41375-018-0178-x
Crooke, S.T., Baker, B.F., Crooke, R.M. and Liang, X.-H. (2021) Antisense Technology: An Overview and Prospectus. Nature Reviews Drug Discovery, 20, 427-453. https://doi.org/10.1038/s41573-021-00162-z
Zeng, Y. and Cullen, B.R. (2005) Efficient Processing of Primary microRNA Hairpins by Drosha Requires Flanking Nonstructured RNA Sequences. Journal of Biological Chemistry, 280, 27595-27603. https://doi.org/10.1074/jbc.M504714200
Schuster, S.L. and Hsieh, A.C. (2019) The Untranslated Regions of mRNAs in Cancer. Trends in Cancer, 5, 245-262. https://doi.org/10.1016/j.trecan.2019.02.011
Kher, G., Trehan, S. and Misra, A. (2011) Antisense Oligonucleotides and RNA Interference. Challenges in Delivery of Therapeutic Genomics and Proteomics, 325-386. https://doi.org/10.1016/B978-0-12-384964-9.00007-4
Ryczek, N., Łyś, A. and Makałowska, I. (2023) The Functional Meaning of 5’UTR in Protein-Coding Genes. International Journal of Molecular Sciences, 24, Article No. 2976. https://doi.org/10.3390/ijms24032976
Cheng, W., Gao, A., Lin, H. and Zhang, W. (2022\) Novel Roles of METTL1/WDR4 in Tumor via m7G Methylation. Molecular Therapy-Oncolytics, 26, 27-34. https://doi.org/10.1016/j.omto.2022.05.009
Xia, P., et al. (2021) MYC-Targeted WDR4 Promotes Proliferation, Metastasis, and Sorafenib Resistance by Inducing CCNB1 Translation in Hepatocellular Carcinoma. Cell Death & Disease, 12, Article No. 691. https://doi.org/10.1038/s41419-021-03973-5
Champagne, J., et al. (2021) Oncogene-Dependent Sloppiness in mRNA Translation. Molecular Cell, 81, 4709-4721. https://doi.org/10.1016/j.molcel.2021.09.002
Park, J.H., Pyun, W.Y. and Park, H.W. (2020) Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells, 9, Article No. 2308. https://doi.org/10.3390/cells9102308
Li, F., Yang, Q., He, A.T. and Yang, B.B. (2021) Circular RNAs in Cancer: Limitations in Functional Studies and Diagnostic Potential. Seminars in Cancer Biology, 75, 49-61. https://doi.org/10.1016/j.semcancer.2020.10.002
Xu, Y., et al. (2019) Translation Control of the Immune Checkpoint in Cancer and Its Therapeutic Targeting. Nature Medicine, 25, 301-311. https://doi.org/10.1038/s41591-018-0321-2
Scoles, D.R., Minikel, E.V. and Pulst, S.M. (2019) Antisense Oligonucleotides: A Primer. Neurology Genetics, 5, e323. https://doi.org/10.1212/NXG.0000000000000323
Dhuri, K., et al. (2020) Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. Journal of Clinical Medicine, 9, Article No. 2004. https://doi.org/10.3390/jcm9062004
Wurster, C.D. and Ludolph, A.C. (2018) Antisense Oligonucleotides in Neurological Disorders. Therapeutic Advances in Neurological Disorders, 11, Article ID: 1756286418776932. https://doi.org/10.1177/1756286418776932
El Marabti, E. and Younis, I. (22018) The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer. Frontiers in Molecular Biosciences, 5, Article 80. https://doi.org/10.3389/fmolb.2018.00080
Lockhart, A., et al. (2019) RNase H1 and H2 Are Differentially Regulated to Process RNA-DNA Hybrids. Cell Reports, 29, 2890-2900. https://doi.org/10.1016/j.celrep.2019.10.108
Lacy, K.A.D., et al. (2022) RNA Modifications Can Affect RNase H1-Mediated PS-ASO Activity. Molecular Therapy-Nucleic Acids, 28, 814-828. https://doi.org/10.1016/j.omtn.2022.05.024
Usman, N. and Blatt, L.M. (2000) Nuclease-Resistant Synthetic Ribozymes: Developing a New Class of Therapeutics. The Journal of Clinical Investigation, 106, 1197-1202. https://doi.org/10.1172/JCI11631
Karpel-Massler, G., Wirtz, C.R. and Halatsch, M.-E. (2010) Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme. Molecules, 15, 4670-4678. https://doi.org/10.3390/molecules15074670
Scott, W.G., Horan, L.H. and Martick, M. (2013) The Hammerhead Ribozyme: Structure, Catalysis, and Gene Regulation. In: Soukup, G.A., Ed., Progress in Molecular Biology and Translational Science, Vol. 120, Elsevier, Amsterdam, 1-23. https://doi.org/10.1016/B978-0-12-381286-5.00001-9
Wong, B.C., Shahid, U. and Tan, H.S. (2022) Ribozymes as Therapeutic Agents Against Infectious Diseases. In: Vlasova-St. Louis, I., Ed., RNA Therapeutics: History, Design, Manufacturing, and Applications, IntechOpen, London.
van Ens, D., et al. (2020) PD-L1 siRNA-Mediated Silencing in Acute Myeloid Leukemia Enhances Anti-Leukemic T Cell Reactivity. Bone Marrow Transplantation, 55, 2308-2318. https://doi.org/10.1038/s41409-020-0966-6
Karami, H., et al. (2014) Down-Regulation of Mcl-1 by Small Interference RNA Induces Apoptosis and Sensitizes HL-60 Leukemia Cells to Etoposide. Asian Pacific Journal of Cancer Prevention, 15, 629-635. https://doi.org/10.7314/APJCP.2014.15.2.629
Adams, S.W. and Emerson, S.G. (1998) Gene Therapy for Leukemia and Lymphoma. Hematology/Oncology Clinics of North America, 12, 631-648. https://doi.org/10.1016/S0889-8588(05)70012-5
Fathullahzadeh, S., Mirzaei, H., Honardoost, M., Sahebkar, A. and Salehi, M. (2016) Circulating microRNA-192 as a Diagnostic Biomarker in Human Chronic Lymphocytic Leukemia. Cancer Gene Therapy, 23, 327-332. https://doi.org/10.1038/cgt.2016.34
Mardani, R., et al. (2019) MicroRNA in Leukemia: Tumor Suppressors and Oncogenes with Prognostic Potential. Journal of Cellular Physiology, 234, 8465-8486. https://doi.org/10.1002/jcp.27776
Cimmino, A., et al. (2005) MiR-15 and miR-16 Induce Apoptosis by Targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102, 13944-13949. https://doi.org/10.1073/pnas.0506654102
Javandoost, E., Firoozi-Majd, E., Rostamian, H., Khakpoor-Koosheh, M. and Mirzaei, H.R. (2020) Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis. Current Medicinal Chemistry, 27, 282-297. https://doi.org/10.2174/0929867326666190911114842
Wallace, J.A. and O’Connell, R.M. (2017) MicroRNAs and Acute Myeloid Leukemia: Therapeutic Implications and Emerging Concepts. Blood, 130, 1290-1301. https://doi.org/10.1182/blood-2016-10-697698
Liang, X.-H., Shen, W. and Crooke, S.T. (2017) Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. In: Li, L.-C., Ed., RNA Activation. Advances in Experimental Medicine and Biology, Vol. 983, Springer, Singapore, 129-146. https://doi.org/10.1007/978-981-10-4310-9_9
Liang, X.-H., et al. (2016) Translation Efficiency of mRNAs Is Increased by Antisense Oligonucleotides Targeting Upstream Open Reading Frames. Nature Biotechnology, 34, 875-880. https://doi.org/10.1038/nbt.3589
Roberts, T.C., Langer, R. and Wood, M.J. (2020) Advances in Oligonucleotide Drug Delivery. Nature Reviews Drug Discovery, 19, 673-694. https://doi.org/10.1038/s41573-020-0075-7
Liang, X., Li, D., Leng, S. and Zhu, X. (2020) RNA-Based Pharmacotherapy for Tumors: From Bench to Clinic and Back. Biomedicine & Pharmacotherapy, 125, Article ID: 109997. https://doi.org/10.1016/j.biopha.2020.109997
Davis, S., Lollo, B., Freier, S. and Esau, C. (2006) Improved Targeting of miRNA with Antisense Oligonucleotides. Nucleic Acids Research, 34, 2294-2304. https://doi.org/10.1093/nar/gkl183
Mulhbacher, J., St-Pierre, P. and Lafontaine, D.A. (2010) Therapeutic Applications of Ribozymes and Riboswitches. Current Opinion in Pharmacology, 10, 551-556. https://doi.org/10.1016/j.coph.2010.07.002
Wu, Y., et al. (1999) Inhibition of Bcr-Abl Oncogene Expression by Novel Deoxyribozymes (DNAzymes). Human Gene Therapy, 10, 2847-2857. https://doi.org/10.1089/10430349950016573
Pastor, F., et al. (2018) An RNA Toolbox for Cancer Immunotherapy. Nature Reviews Drug Discovery, 17, 751-767. https://doi.org/10.1038/nrd.2018.132
Rosenblum, D., Joshi, N., Tao, W., Karp, J.M. and Peer, D. (2018) Progress and Challenges towards Targeted Delivery of Cancer Therapeutics. Nature Communications, 9, Article No. 1410. https://doi.org/10.1038/s41467-018-03705-y
Zhou, Z., et al. (2017) Nonviral Cancer Gene Therapy: Delivery Cascade and Vector Nanoproperty Integration. Advanced Drug Delivery Reviews, 115, 115-154. https://doi.org/10.1016/j.addr.2017.07.021